JP2016511254A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511254A5 JP2016511254A5 JP2015559593A JP2015559593A JP2016511254A5 JP 2016511254 A5 JP2016511254 A5 JP 2016511254A5 JP 2015559593 A JP2015559593 A JP 2015559593A JP 2015559593 A JP2015559593 A JP 2015559593A JP 2016511254 A5 JP2016511254 A5 JP 2016511254A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 41
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 102000003802 alpha-Synuclein Human genes 0.000 claims 14
- 108090000185 alpha-Synuclein Proteins 0.000 claims 14
- 238000000034 method Methods 0.000 claims 9
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/781,158 US20140241987A1 (en) | 2013-02-28 | 2013-02-28 | Alpha-synuclein antibodies and uses thereof |
| US13/781,158 | 2013-02-28 | ||
| US14/138,347 US9534044B2 (en) | 2013-02-28 | 2013-12-23 | Alpha-synuclein antibodies and uses thereof |
| US14/138,347 | 2013-12-23 | ||
| PCT/IB2014/059287 WO2014132210A1 (en) | 2013-02-28 | 2014-02-27 | Alpha-synuclein antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016511254A JP2016511254A (ja) | 2016-04-14 |
| JP2016511254A5 true JP2016511254A5 (OSRAM) | 2017-03-30 |
| JP6261621B2 JP6261621B2 (ja) | 2018-01-17 |
Family
ID=51388371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015559593A Active JP6261621B2 (ja) | 2013-02-28 | 2014-02-27 | アルファ−シヌクレイン抗体及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9534044B2 (OSRAM) |
| EP (1) | EP2961774B1 (OSRAM) |
| JP (1) | JP6261621B2 (OSRAM) |
| KR (1) | KR101990096B1 (OSRAM) |
| CN (1) | CN105121473B (OSRAM) |
| WO (1) | WO2014132210A1 (OSRAM) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3191599T3 (pl) * | 2014-09-11 | 2023-12-27 | Board Of Regents Of The University Of Texas System | Wykrywanie nieprawidłowo sfałdowanych białek |
| JP2017536102A (ja) * | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| WO2016075516A1 (en) * | 2014-11-14 | 2016-05-19 | United Arab Emirates University | Compounds for use as imaging agents |
| EP3273994B1 (en) | 2015-03-27 | 2021-12-01 | University of Southern California | Car t-cell therapy directed to lhr for the treatment of solid tumors |
| CN107847601A (zh) | 2015-06-04 | 2018-03-27 | 南加利福尼亚大学 | Lym‑1和lym‑2靶向的car细胞免疫疗法 |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| KR102499438B1 (ko) * | 2016-06-02 | 2023-02-14 | 메디뮨 리미티드 | 알파-시누클레인에 대한 항체 및 이의 용도 |
| US10245320B2 (en) | 2016-09-30 | 2019-04-02 | Enzo Biochem, Inc. | Immunomodulatory pharmaceutical compositions and methods of use thereof |
| AU2017359944B2 (en) * | 2016-11-15 | 2024-07-18 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
| ES3008133T3 (en) | 2016-12-16 | 2025-03-21 | H Lundbeck As | Agents, uses and methods |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| WO2018128454A1 (ko) * | 2017-01-06 | 2018-07-12 | 에이비엘바이오 주식회사 | 항 α-SYN 항체 및 그 용도 |
| MX2019008029A (es) | 2017-01-06 | 2019-12-11 | Abl Bio Inc | Anticuerpo anti-alfa-sinucleina y su uso. |
| KR102573778B1 (ko) * | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
| IL270361B2 (en) | 2017-05-01 | 2025-04-01 | Univ Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| WO2019018607A1 (en) * | 2017-07-20 | 2019-01-24 | Enzo Biochem, Inc. | IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF |
| US11155608B2 (en) | 2017-08-23 | 2021-10-26 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against pathological alpha-synuclein, and methods using same |
| US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
| KR102508933B1 (ko) * | 2017-11-17 | 2023-03-13 | 에이비엘바이오 주식회사 | 알파-시누클레인에 대한 항체 및 그 용도 |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| CN116731173A (zh) * | 2017-12-14 | 2023-09-12 | Abl生物公司 | 抗a-syn/igf1r的双特异性抗体及其用途 |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| WO2020009482A1 (ko) * | 2018-07-03 | 2020-01-09 | 에이비엘바이오 주식회사 | 항 알파-시누클레인 항체 및 그 용도 |
| WO2020056418A1 (en) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | System and method of improving sleep |
| AU2019356804B2 (en) | 2018-10-07 | 2025-05-29 | Promis Neurosciences, Inc. | Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof |
| AU2020221324A1 (en) | 2019-02-15 | 2021-09-02 | University Of Southern California | Lym-1 and Lym-2 antibody compositions and improved CAR constructs |
| MA55504A (fr) | 2019-04-01 | 2022-02-09 | Novo Nordisk As | Anticorps dirigés contre le liraglutide et leur utilisation |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| CN110172098B (zh) * | 2019-05-27 | 2023-03-10 | 长春工业大学 | 抗α-突触核蛋白的单克隆抗体及其应用 |
| EA202193058A1 (ru) * | 2019-06-14 | 2022-03-05 | ЭйБиЭл БИО ИНК. | БИСПЕЦИФИЧЕСКОЕ АНТИТЕЛО К -syn/IGF1R И ЕГО ПРИМЕНЕНИЕ |
| EP3999547A4 (en) * | 2019-07-16 | 2023-07-12 | Washington University | ANTI-GRP78 ANTIBODY AND METHOD OF USING THE SAME |
| KR102277871B1 (ko) * | 2019-12-17 | 2021-07-15 | 원광대학교산학협력단 | 소변의 알파-씨누클레인 중합체 측정에 의한 파킨슨병 진단 정보의 수집방법 및 그 키트 |
| NL2025332B1 (en) * | 2020-04-10 | 2021-10-26 | Syngle Therapeutics B V | Novel alpha-synuclein binding antibodies, or antigen binding portions thereof. |
| FI4172199T3 (fi) * | 2020-06-26 | 2025-08-12 | Bioarctic Ab | Alfa-synukleiinin protofibrilliin sitoutuvat vasta-aineet |
| US20230365665A1 (en) | 2020-09-17 | 2023-11-16 | Qatar Foundation For Education, Science And Community Development | ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES |
| WO2022060236A1 (en) * | 2020-09-17 | 2022-03-24 | Qatar Foundation For Education, Science And Community Development | ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES |
| CN113912715B (zh) * | 2021-12-15 | 2022-03-01 | 北京凯祥弘康生物科技有限公司 | 一种抗α-突触核蛋白抗体及其相关产品和应用 |
| CN113912713B (zh) * | 2021-12-15 | 2022-03-08 | 北京凯祥弘康生物科技有限公司 | 一种抗α-突触核蛋白的单克隆抗体及其应用 |
| CN114853887B (zh) * | 2022-03-08 | 2022-12-20 | 骏蓦(北京)生物科技有限公司 | 一种特异性结合α-突触核蛋白的抗体及其应用 |
| CN115032400A (zh) * | 2022-03-28 | 2022-09-09 | 首都医科大学附属北京天坛医院 | α-突触核蛋白在辅助诊断神经退行性疾病中的用途 |
| CN116286668A (zh) * | 2023-02-13 | 2023-06-23 | 贵安新区康顺生物科技有限公司 | 一种杂交瘤细胞株及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL106271A (en) * | 1992-09-03 | 2008-03-20 | Yeda Res & Dev | Ligand to TNF 75P receptor and its preparation |
| US5948658A (en) * | 1996-06-25 | 1999-09-07 | The Trustees Of Columbia University In The City Of New York | Anti-cocaine catalytic antibody |
| US7083950B2 (en) * | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
| GB0228832D0 (en) * | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| CN1905899B (zh) * | 2003-11-20 | 2011-09-28 | 医学免疫公司 | EphA2激动性单克隆抗体及其使用方法 |
| CN103694349A (zh) * | 2006-09-08 | 2014-04-02 | 米迪缪尼有限公司 | 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用 |
| GB0716885D0 (en) | 2007-08-30 | 2007-10-10 | United Arab Emirates Universit | Diagnostic agent |
| CN101570575B (zh) * | 2008-04-30 | 2012-02-29 | 北京市肿瘤防治研究所 | Sncg的单克隆抗体及其应用 |
| WO2010069603A1 (en) * | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
| JP5769316B2 (ja) * | 2009-08-06 | 2015-08-26 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| CN101692092B (zh) * | 2009-09-24 | 2013-04-10 | 首都医科大学宣武医院 | 定量检测人血清中自体α-突触核蛋白抗体的方法 |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| DE102011008153B4 (de) | 2011-01-08 | 2018-08-09 | Aj Roboscreen Gmbh | Verfahren zur Herstellung eines monoklonalen Antikörpers gegen oligomeres Alpha-Synuclein |
| LT2723379T (lt) | 2011-06-23 | 2018-10-25 | Biogen International Neuroscience Gmbh | Anti-alfa sinukleiną rišančios molekulės |
-
2013
- 2013-12-23 US US14/138,347 patent/US9534044B2/en active Active
-
2014
- 2014-02-27 WO PCT/IB2014/059287 patent/WO2014132210A1/en not_active Ceased
- 2014-02-27 CN CN201480011360.XA patent/CN105121473B/zh active Active
- 2014-02-27 KR KR1020157025875A patent/KR101990096B1/ko active Active
- 2014-02-27 JP JP2015559593A patent/JP6261621B2/ja active Active
- 2014-02-27 EP EP14756906.5A patent/EP2961774B1/en active Active
-
2016
- 2016-11-18 US US15/355,543 patent/US10208111B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016511254A5 (OSRAM) | ||
| JP2011528901A5 (OSRAM) | ||
| JP2014528695A5 (OSRAM) | ||
| HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
| HRP20231196T1 (hr) | Nova protutijela koja se specifično vežu na epitope zika virusa i njihova upotreba | |
| HRP20192267T1 (hr) | Terapeutski agens ili profilaktički agens za demenciju | |
| HRP20201729T1 (hr) | Antitijela protiv aktivina a i njihova primjena | |
| JP2016503065A5 (OSRAM) | ||
| JP2017522903A5 (OSRAM) | ||
| JP2013500940A5 (OSRAM) | ||
| JP2018527919A5 (OSRAM) | ||
| JP2015505665A5 (OSRAM) | ||
| JP2017205118A5 (OSRAM) | ||
| RU2015141418A (ru) | Антитела, связывающие il-4 и/или il-13, и их применение | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| HRP20130877T1 (hr) | Antitijela koja neutraliziraju humani citomegalovirus i njihova primjena | |
| JP2017529097A5 (OSRAM) | ||
| JP2015530971A5 (OSRAM) | ||
| JP2016029056A5 (OSRAM) | ||
| JP2016524592A5 (OSRAM) | ||
| FI3525583T3 (fi) | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä | |
| JP2016536322A5 (OSRAM) | ||
| JP2015531768A5 (OSRAM) | ||
| HRP20220891T1 (hr) | Protutijela, primjene i postupci | |
| JP2013524774A5 (OSRAM) |